eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
10 juil. 2024 08h00 HE
|
Ovid Therapeutics Inc.
Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibitionOV329...
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
01 juil. 2024 08h00 HE
|
Ovid Therapeutics Inc.
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse eventsSecondary endpoint results indicate that the target...
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
17 juin 2024 06h55 HE
|
Ovid Therapeutics Inc.
Takeda’s Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizure frequency and showed clinically meaningful and significant effects in multiple key...
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
14 mai 2024 08h00 HE
|
Ovid Therapeutics Inc.
Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data are anticipated in Takeda's H1 2024 fiscal yearA Phase 1,...
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
13 mai 2024 07h00 HE
|
Ovid Therapeutics Inc.
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
04 avr. 2024 08h00 HE
|
Ovid Therapeutics Inc.
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies...
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
08 mars 2024 08h00 HE
|
Ovid Therapeutics Inc.
Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) completed enrollment; Takeda anticipates topline data readout by or...
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
28 févr. 2024 08h00 HE
|
Ovid Therapeutics Inc.
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
06 févr. 2024 08h00 HE
|
Ovid Therapeutics Inc.
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
01 déc. 2023 07h30 HE
|
Ovid Therapeutics Inc.
Posters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class GABA aminotransferase inhibitor Disease models provide...